New insights into the complex role of mitochondria in Parkinson’s disease
Open accessThe DOI matches its Crossref record; 281 of the 281 references it cites were found in a registry or an index.
Abstract
New discoveries providing insights into mitochondrial bioenergetics, their dynamic interactions as well as their role in cellular homeostasis have dramatically advanced our understanding of the neurodegenerative process of Parkinson's disease (PD). Respiratory chain impairment is a key feature in sporadic PD patients and there is growing evidence that links proteins encoded by PD-associated genes to disturbances in mitochondrial function. Against the backdrop of latest advances in the development of PD treatments that target mitochondria, we aim to give an overview of the literature published in the last three decades on the significance of mitochondria in the pathogenesis of PD. We describe the contribution of mitochondrial genome alterations and PD-associated genes to mitochondrial maintenance. We highlight mitophagy as a key mechanism in neurodegeneration. Moreover, we focus on the reciprocal interaction between alpha-synuclein aggregation and mitochondrial dysfunction. We discuss a novel trafficking pathway involving mitochondrial-derived vesicles within the context of PD and provide a synopsis of the most recently emerging topics in PD research with respect to mitochondria. This includes the relationship between mitochondria and cell-mediated immunity, the ER-mitochondria axis, sirtuin-mediated mitochondrial stress response and the role of micro RNAs in the aetiology of PD. In addition, recent studies have challenged the neuro-centric view of PD pathology, moving microglia and astrocytes into the research spotlight. Greater insights into these mechanisms may hold the key for the development of novel targeted therapies, addressing the need for a disease-modifying treatment, which has remained elusive to date.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–281 of 281
Bioenergetic Consequences of PINK1 Mutations in Parkinson Disease
Abramov, A. Y., Gegg, M., Grunewald, A., Wood, N. W., Klein, C., & Schapira, A. H. V. (2011) · PLoS ONE · doi:10.1371/journal.pone.0025622 · Cited by 98
Pozo Devoto, V. M., Dimopoulos, N., Alloatti, M., Pardi, M. B., Saez, T. M., Otero, M. G., Cromberg, L. E., Marín-Burgin, A., Scassa, M. E., Stokin, G. B., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-05334-9 · Cited by 97
Calcium, mitochondrial dysfunction and slowing the progression of Parkinson's disease
Surmeier, D. J., Halliday, G. M., & Simuni, T. (2017) · Experimental Neurology · doi:10.1016/j.expneurol.2017.08.001 · Cited by 97
Yuan, Z., Qu, J. T., Xue, F., Zheng, Y., Yang, B., Chang, Y., Yang, H., & Zhang, J. (2018) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2018.02.011 · Cited by 97
Mitophagy in Parkinson’s Disease: Pathogenic and Therapeutic Implications
Gao, F., Yang, J. Y., Wang, D., Li, C., Fu, Y., Wang, H., He, W., & Zhang, J. (2017) · Frontiers in Neurology · doi:10.3389/fneur.2017.00527 · Cited by 95
Frequency of the D620N Mutation in VPS35 in Parkinson Disease
Kumar, K. R., Weissbach, A., Heldmann, M., Kasten, M., Tunc, S., Sue, C. M., Svetel, M., Kostić, V. S., Segura-Aguilar, J., Ramirez, A., et al. (2012) · Archives of Neurology · doi:10.1001/archneurol.2011.3367 · Cited by 94
Self-citationThe Impact of Pathogenic Mitochondrial DNA Mutations on Substantia Nigra Neurons
Reeve, A., Meagher, M., Lax, N., Simcox, E., Hepplewhite, P., Jaros, E., & Turnbull, D. (2013) · Journal of Neuroscience · doi:10.1523/jneurosci.3525-12.2013 · Cited by 92
Impaired oxidative decarboxylation of pyruvate in fibroblasts from patients with Parkinson's disease
Mytilineou, C., Werner, P., Molinari, S., Rocco, A. D., Cohen, G., & Yahr, M. D. (1994) · Journal of Neural Transmission - Parkinsons Disease and Dementia Section · doi:10.1007/bf02260943 · Cited by 92
Barbiero, J. K., Santiago, R. M., Persike, D. S., Fernandes, M. J. D. S., Tonin, F. S., Cunha, C. D., Boschen, S. L., Lima, M. M. S., & Vital, M. A. B. F. (2014) · Behavioural Brain Research · doi:10.1016/j.bbr.2014.08.014 · Cited by 91
Klivènyi, P., Gardian, G., Calingasan, N. Y., Yang, L., & Beal, M. F. (2003) · Journal of Molecular Neuroscience · doi:10.1385/jmn:21:3:191 · Cited by 91
Choi, I., Kim, J., Jeong, H., Kim, B., Jou, I., Park, S. M., Chen, L., Kang, U., Zhuang, X., & Joe, E. (2013) · Glia · doi:10.1002/glia.22475 · Cited by 89
Reinhardt, P., Glatza, M., Hemmer, K., Tsytsyura, Y., Thiel, C. S., Höing, S., Moritz, S., Parga, J. A., Wagner, L., Bruder, J. M., et al. (2013) · PLoS ONE · doi:10.1371/annotation/6a917a2e-df4a-4ad9-99bb-6aa7218b833e · Cited by 89
Cardiolipin promotes electron transport between ubiquinone and complex I to rescue PINK1 deficiency
Vos, M. H., Geens, A., Böhm, C., Deaulmerie, L., Swerts, J., Rossi, M., Craessaerts, K., Leites, E. P., Seibler, P., Raković, A., et al. (2017) · The Journal of Cell Biology · doi:10.1083/jcb.201511044 · Cited by 88
FACS-Assisted CRISPR-Cas9 Genome Editing Facilitates Parkinson's Disease Modeling
Arias, J., Jarazo, J., Qing, X., Walter, J., Gomez‐Giro, G., Nickels, S., Zaehres, H., Schöler, H. R., & Schwamborn, J. C. (2017) · Stem Cell Reports · doi:10.1016/j.stemcr.2017.08.026 · Cited by 88
Genetic mouse models for Parkinson's disease display severe pathology in glial cell mitochondria
Schmidt, S., Linnartz, B., Mendritzki, S., Sczepan, T., Lubbert, M., Stichel, C. C., & Lubbert, H. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddq564 · Cited by 87
Rahimmi, A., Khosrobakhsh, F., Izadpanah, E., Moloudi, M. R., & Hassanzadeh, K. (2015) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2015.02.007 · Cited by 85
Parkin functionally interacts with PGC-1α to preserve mitochondria and protect dopaminergic neuron s
Zheng, L., Bernard-Marissal, N., Moullan, N., D’Amico, D., Auwerx, J., Moore, D. J., Knott, G., Aebischer, P., & Schneider, B. L. (2017) · Human Molecular Genetics · doi:10.1093/hmg/ddw418 · Cited by 84
Schwab, A. J., & Ebert, A. D. (2015) · Stem Cell Reports · doi:10.1016/j.stemcr.2015.11.004 · Cited by 83
Shahrani, M. M. A., Heales, S., Hargreaves, I. P., & Orford, M. (2017) · Journal of Clinical Medicine · doi:10.3390/jcm6110100 · Cited by 83
Pogson, J. H., Ivatt, R. M., Sanchez-Martinez, A., Tufi, R., Wilson, E., Mortiboys, H., & Whitworth, A. J. (2014) · PLoS Genetics · doi:10.1371/journal.pgen.1004815 · Cited by 81
Belluzzi, E., Bisaglia, M., Lazzarini, E., Tabares, L. C., Beltramini, M., & Bubacco, L. (2012) · PLoS ONE · doi:10.1371/journal.pone.0038026 · Cited by 81
Decreased sirtuin deacetylase activity in LRRK2 G2019S iPSC-derived dopaminergic neurons
Schwab, A. J., Sison, S. L., Meade, M. R., Broniowska, K. A., Corbett, J. A., & Ebert, A. D. (2017) · Stem Cell Reports · doi:10.1016/j.stemcr.2017.10.010 · Cited by 80 · cited 2×
“However, while the treatment reduced mitochondrial velocity, it had no effect on SIRT1, SIRT2, or SIRT3 expression levels or any other mitochondrial function phenotypes observed in the cells (Schwab et al., 2017).”
Liu, L., Peritore, C., Rogers, J. G., Kayhan, M. A., & Dönmez, G. (2015) · Neurochemical Research · doi:10.1007/s11064-014-1507-8 · Cited by 80
Genetics of Parkinson's Disease
Kumar, K., Djarmati-Westenberger, A., & Grünewald, A. (2011) · Seminars in Neurology · doi:10.1055/s-0031-1299782 · Cited by 79
Self-citationMitochondrial dysfunction in Parkinson disease: evidence in mutant PARK2 fibroblasts
Zanellati, M. C., Monti, V., Barzaghi, C., Reale, C., Nardocci, N., Albanese, A., Valente, E. M., Ghezzi, D., & Garavaglia, B. (2015) · Frontiers in Genetics · doi:10.3389/fgene.2015.00078 · Cited by 79
Martínez, M. (2000) · Brain Research · doi:10.1016/s0006-8993(00)02005-9 · Cited by 79
Suzuki, S., Akamatsu, W., Kisa, F., Sone, T., Ishikawa, K., Kuzumaki, N., Katayama, H., Miyawaki, A., Hattori, N., & Okano, H. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.12.188 · Cited by 78
Gleave, J. A., Arathoon, L. R., Trinh, D., Lizal, K. E., Giguère, N., Barber, J., Najarali, Z., Khan, M. H., Thiele, S. L., Semmen, M. S., et al. (2017) · Neurobiology of Disease · doi:10.1016/j.nbd.2017.06.009 · Cited by 78
Effect of coenzyme Q10 on the mitochondrial function of skin fibroblasts from Parkinson patients
Winkler‐Stuck, K., Wiedemann, F. R., Wallesch, C., & Kunz, W. S. (2004) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2004.02.003 · Cited by 77
MicroRNAs in Parkinson's disease and emerging therapeutic targets
Peplow, P., & Martinez, B. (2017) · Neural Regeneration Research · doi:10.4103/1673-5374.221147 · Cited by 77
Emerging roles of mitochondria in the evolution, biogenesis, and function of peroxisomes
Mohanty, A., & McBride, H. M. (2013) · Frontiers in Physiology · doi:10.3389/fphys.2013.00268 · Cited by 76
Zanon, A., Kalvakuri, S., Raković, A., Foco, L., Guida, M., Schwienbacher, C., Serafin, A., Rudolph, F., Trilck, M., Grünewald, A., et al. (2017) · Human Molecular Genetics · doi:10.1093/hmg/ddx132 · Cited by 75
Self-citationGenetics of Parkinson disease and other movement disorders
Kumar, K. R., Lohmann, K., & Klein, C. (2012) · Current Opinion in Neurology · doi:10.1097/wco.0b013e3283547627 · Cited by 74
Self-citationPinto, M., Nissanka, N., & Moraes, C. T. (2017) · Journal of Neuroscience · doi:10.1523/jneurosci.1384-17.2017 · Cited by 72
Mitochondria and α-Synuclein: Friends or Foes in the Pathogenesis of Parkinson’s Disease?
Faustini, G., Bono, F., Valerio, A., Pizzi, M., Spano, P., & Bellucci, A. (2017) · Genes · doi:10.3390/genes8120377 · Cited by 69
Nrf2 Signaling Contributes to the Neuroprotective Effects of Urate against 6-OHDA Toxicity
Zhang, N., Shu, H., Huang, T., Zhang, Q., Li, D., Zhang, G., Peng, X., Liu, C., Luo, W., & Hu, L. (2014) · PLoS ONE · doi:10.1371/journal.pone.0100286 · Cited by 67
Sirtuins in mitochondrial stress: Indispensable helpers behind the scenes
Lin, S., Xing, H., Zang, T., Ruan, X., Wo, L., & He, M. (2018) · Ageing Research Reviews · doi:10.1016/j.arr.2018.03.006 · Cited by 67
Mitochondria-targeted antioxidant effects of S(-) and R(+) pramipexole
Ferrari-Toninelli, G., Maccarinelli, G., Uberti, D., Buerger, E., & Memo, M. (2010) · BMC Pharmacology · doi:10.1186/1471-2210-10-2 · Cited by 65
Fibroblast Biomarkers of Sporadic Parkinson’s Disease and LRRK2 Kinase Inhibition
Smith, G. A., Jansson, J., Rocha, E. M., Osborn, T., Hallett, P. J., & Isacson, O. (2016) · Molecular Neurobiology · doi:10.1007/s12035-015-9435-4 · Cited by 64
Evidence that phosphorylated ubiquitin signaling is involved in the etiology of Parkinson’s disease
Shiba-Fukushima, K., Ishikawa, K.-I., Inoshita, T., Izawa, N., Takanashi, M., Sato, S., Onodera, O., Akamatsu, W., Okano, H., Imai, Y., et al. (2017) · Human Molecular Genetics · doi:10.1093/hmg/ddx201 · Cited by 64
Sante, G. D., Pestell, T. G., Casimiro, M. C., Bisetto, S., Powell, M. J., Lisanti, M. P., Cordon‐Cardo, C., Castillo-Martín, M., Bonal, D. M., Debattisti, V., et al. (2014) · American Journal Of Pathology · doi:10.1016/j.ajpath.2014.09.014 · Cited by 63
Bioenergetic and proteolytic defects in fibroblasts from patients with sporadic Parkinson's disease
Ambrosi, G., Ghezzi, C., Sepe, S., Milanese, C., Payán‐Gómez, C., Bombardieri, C. R., Armentero, M., Zangaglia, R., Pacchetti, C., Mastroberardino, P. G., et al. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.05.008 · Cited by 61
Striatal neuroprotection with methylene blue
Rojas, J. C., Simola, N., Kermath, B. A., Kane, J. R., Schallert, T., & Gonzalez-Lima, F. (2009) · Neuroscience · doi:10.1016/j.neuroscience.2009.07.012 · Cited by 60
Lipid profiling of parkin‐mutant human skin fibroblasts
Lobasso, S., Tanzarella, P., Vergara, D., Maffia, M., Cocco, T., & Corcelli, A. (2017) · Journal of Cellular Physiology · doi:10.1002/jcp.25815 · Cited by 60
Haylett, W. L., Swart, C., van der Westhuizen, F. H., Dyk, H. C. V., van der Merwe, L., van der Merwe, C., Loos, B., Carr, J. A., Kinnear, C. J., & Bardien, S. (2016) · Parkinson s Disease · doi:10.1155/2016/1819209 · Cited by 59
Ultradeep mapping of neuronal mitochondrial deletions in Parkinson's disease
Nido, G. S., Dölle, C., Flønes, I. H., Tuppen, H. A. L., Alves, G. W., Tysnes, O., Haugarvoll, K., & Tzoulis, C. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.10.024 · Cited by 58
PINK1-Interacting Proteins: Proteomic Analysis of Overexpressed PINK1
Rakovic, A., Grünewald, A., Voges, L., Hofmann, S., Orolicki, S., Lohmann, K., & Klein, C. (2011) · Parkinson's Disease · doi:10.4061/2011/153979 · Cited by 54
Self-citationOxidative stress in skin fibroblasts cultures from patients with Parkinson's disease
del Hoyo, P., García‐Redondo, A., Bustos, F., Molina, J. A., Sayed, Y., Alonso‐Navarro, H., Caballero, L., Arenas, J., Agúndez, J. A. G., & Jiménez‐Jiménez, F. J. (2010) · BMC Neurology · doi:10.1186/1471-2377-10-95 · Cited by 53
DJ ‐1 modulates mitochondrial response to oxidative stress: clues from a novel diagnosis of PARK7
Nottia, M. D., Masciullo, M., Verrigni, D., Petrillo, S., Modoni, A., Rizzo, V., Giuda, D. D., Rizza, T., Niceta, M., Torraco, A., et al. (2016) · Clinical Genetics · doi:10.1111/cge.12841 · Cited by 53
López-Fabuel, I., Martin-Martin, L., Resch-Beusher, M., Azkona, G., Sánchez‐Pernaute, R., & Bolaños, J. P. (2017) · Neurochemistry International · doi:10.1016/j.neuint.2017.03.023 · Cited by 53
Elstner, M., Müller, S. K., Leidolt, L., Laub, C., Krieg, L., Schlaudraff, F., Liss, B., Morris, C., Turnbull, D. M., Masliah, E., et al. (2011) · Molecular Brain · doi:10.1186/1756-6606-4-43 · Cited by 50
Mitochondrial ROS-mediated post-transcriptional regulation of α-synuclein through miR-7 and miR-153
Je, G., & Kim, Y. (2017) · Neuroscience Letters · doi:10.1016/j.neulet.2017.09.065 · Cited by 50
DJ-1 activates SIRT1 through its direct binding to SIRT1
Takahashi-Niki, K., Ganaha, Y., Niki, T., Nakagawa, S., Kato-Ose, I., Iguchi‐Ariga, S. M. M., & Ariga, H. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.04.084 · Cited by 49
Parkinson's disease-associated pathogenic VPS35 mutation causes complex I deficits
Zhou, L., Wang, W., Hoppel, C., Liu, J., & Zhu, X. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2017.07.032 · Cited by 49
Enhanced vulnerability of PARK6 patient skin fibroblasts to apoptosis induced by proteasomal stress
Klinkenberg, M., Thurow, N., Gispert, S., Ricciardi, F., Eich, F., Prehn, J. H. M., Auburger, G. W. J., & Kögel, D. (2010) · Neuroscience · doi:10.1016/j.neuroscience.2009.12.068 · Cited by 48
Gustafsson, G., Lindström, V., Rostami, J., Nordström, E., Lannfelt, L., Bergström, J., Ingelsson, M., & Erlandsson, A. (2017) · Journal of Neuroinflammation · doi:10.1186/s12974-017-1018-z · Cited by 48
Chuang, C., Chang, J., Cheng, F., Liu, K., Su, H., & Liu, C. (2017) · Life Sciences · doi:10.1016/j.lfs.2017.10.003 · Cited by 46
Lázaro, S., Gamarra, D., & Val, M. D. (2015) · Molecular Immunology · doi:10.1016/j.molimm.2015.04.014 · Cited by 45
Coexistence of mutations in PINK1 and mitochondrial DNA in early onset parkinsonism
Piccoli, C., Ripoli, M. C., Quarato, G., Scrima, R., D’Aprile, A., Boffoli, D., Margaglione, M., Criscuolo, C., Michele, G. D., Sardanelli, A. M., et al. (2008) · Journal of Medical Genetics · doi:10.1136/jmg.2008.058628 · Cited by 44
Wang, W., Ma, X., Zhou, L., Liu, J., & Zhu, X. (2016) · Human Molecular Genetics · doi:10.1093/hmg/ddw430 · Cited by 43
Grünewald, A., Arns, B., Meier, B., Brockmann, K., Tadić, V., & Klein, C. (2013) · Antioxidants and Redox Signaling · doi:10.1089/ars.2013.5737 · Cited by 42
Self-citationAzkona, G., de Maturana, R. L., del Río, P., Sousa, A., Vázquez, N., Zubiarrain, A., Jiménez-Blasco, D., Bolaños, J. P., Morales, B., Auburger, G. W. J., et al. (2016) · Molecular Neurobiology · doi:10.1007/s12035-016-0303-7 · Cited by 41
Rompuy, A. V., Lobbestael, E., der Perren, A. V., den Haute, C. V., & Baekelandt, V. (2014) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0000000000000039 · Cited by 40
Mitophagy and the therapeutic clearance of damaged mitochondria for neuroprotection
East, D. A., & Campanella, M. (2016) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2016.08.019 · Cited by 40
Biju, K. C., Evans, R. C., Shrestha, K., Carlisle, D., Gelfond, J., & Clark, R. A. (2018) · Neuroscience · doi:10.1016/j.neuroscience.2018.04.008 · Cited by 40
Jana, S., Maiti, A. K., Bagh, M. B., Banerjee, K., Das, A., Roy, A., & Chakrabarti, S. (2007) · Brain Research · doi:10.1016/j.brainres.2006.09.100 · Cited by 39
Shin, E., Nam, Y., Lee, J. W., Nguyen, P.-K. T., Yoo, J. E., Tran, T.-V., Jeong, J. H., Jang, C., Oh, Y. J., Youdim, M. B. H., et al. (2015) · Molecular Neurobiology · doi:10.1007/s12035-015-9527-1 · Cited by 39
Gene Therapy: A Promising Approach for Neuroprotection in Parkinson’s Disease?
Valdés, P., & Schneider, B. L. (2016) · Frontiers in Neuroanatomy · doi:10.3389/fnana.2016.00123 · Cited by 39
Prajapati, P., Sripada, L., Singh, K., Roy, M., Bhatelia, K., Dalwadi, P., & Singh, R. (2017) · Molecular Neurobiology · doi:10.1007/s12035-017-0664-6 · Cited by 38
Mo, J., Liu, L.-Y., Peng, W.-B., Rao, J., Liu, Z., & Cui, L. (2017) · BMC Neurology · doi:10.1186/s12883-017-0885-3 · Cited by 36
New Therapeutics to Modulate Mitochondrial Function in Neurodegenerative Disorders
M. Wilkins, H., & K. Morris, J. (2017) · Current Pharmaceutical Design · doi:10.2174/1381612822666161230144517 · Cited by 35
Francardo, V. (2017) · Behavioural Brain Research · doi:10.1016/j.bbr.2017.12.014 · Cited by 34
Peripheral Biomarkers of Parkinson’s Disease Progression and Pioglitazone Effects
Simon, D. K., On behalf of the NINDS NET-PD Investigators, Simuni, T., Elm, J. J., Clark, J., Graebner, A. K., Baker, L., Dunlop, S. R., Emborg, M. E., Kamp, C., et al. (2015) · Journal of Parkinson s Disease · doi:10.3233/jpd-150666 · Cited by 32
van der Merwe, C., Loos, B., Swart, C., Kinnear, C. J., Henning, F., van der Merwe, L., Pillay, K., Muller, N., Zaharie, D., Engelbrecht, L., et al. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.03.151 · Cited by 31
Grünewald, A., Lax, N. Z., Rocha, M. C., Reeve, A. K., Hepplewhite, P. D., Rygiel, K. A., Taylor, R. W., & Turnbull, D. M. (2014) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2014.05.026 · Cited by 31
Self-citationPopulation prevalence and incidence of Parkinson’s disease in an Australian community
Mehta, P., Kifley, A., Wang, J. J., Rochtchina, E., Mitchell, P., & Sue, C. M. (2007) · Internal Medicine Journal · doi:10.1111/j.1445-5994.2007.01433.x · Cited by 30
Self-citationMilanese, C., Tapias, V., Gabriels, S., Cerri, S., Levandis, G., Blandini, F., Tresini, M., Shiva, S., Greenamyre, J. T., Gladwin, M. T., et al. (2017) · Antioxidants and Redox Signaling · doi:10.1089/ars.2017.6992 · Cited by 29
Parkin Type of Early-Onset Parkinson Disease
Brüggemann, N., & Klein, C. (2013) · Europe PMC (PubMed Central) · Cited by 28
Maternal inheritance and mitochondrial DNA variants in familial Parkinson's disease
the Parkinson Study Group - PROGENI Investigators, Simon, D. K., Pankratz, N., Kissell, D. K., Pauciulo, M. W., Halter, C. A., Rudolph, A., Pfeiffer, R. F., Nichols, W. C., & Foroud, T. (2010) · BMC Medical Genetics · doi:10.1186/1471-2350-11-53 · Cited by 27
Unveiling the role of the pesticides paraquat and rotenone on α-synuclein fibrillation in vitro
Maturana, M. G. V., Pinheiro, A. S., de Souza, T. L. F., & Follmer, C. (2014) · NeuroToxicology · doi:10.1016/j.neuro.2014.11.006 · Cited by 25
Smith, E. S., Clark, M. E., Hardy, G. A., Kraan, D. J., Biondo, E., Gonzalez-Lima, F., Cormack, L. K., Monfils, M., & Lee, H. J. (2017) · Neuroscience · doi:10.1016/j.neuroscience.2017.07.001 · Cited by 20
Cited by
The pathogenesis of Parkinson's disease
Morris, H. R., Spillantini, M. G., Sue, C. M., & Williams-Gray, C. H. (2024) · The Lancet · doi:10.1016/s0140-6736(23)01478-2 · Cited by 1,019
Self-citationCellular mitophagy: Mechanism, roles in diseases and small molecule pharmacological regulation
Lu, Y., Li, Z., Zhang, S., Zhang, T., Liu, Y., & Zhang, L. (2023) · Theranostics · doi:10.7150/thno.79876 · Cited by 685
Mitochondria in health, disease, and aging
Harrington, J. S., Ryter, S. W., Plataki, M., Price, D. R., & Choi, A. M. K. (2023) · Physiological Reviews · doi:10.1152/physrev.00058.2021 · Cited by 602
Smajić, S., Prada-Medina, C. A., Landoulsi, Z., Ghelfi, J., Delcambre, S., Dietrich, C., Jarazo, J., Henck, J., Balachandran, S., Pachchek, S., et al. (2022) · Brain · doi:10.1093/brain/awab446 · Cited by 590
“Parkinson’s disease is a neurological disorder that is commonly characterized by a progressive loss of neuromelanin-containing dopaminergic neurons (DaNs) in the substantia nigra (SN).(1,2) Age, genetic and environmental factors contribute to Parkinson’s disease pathogenesis, but disease pathology and aetiology remain…”
Self-citationSignaling pathways in Parkinson’s disease: molecular mechanisms and therapeutic interventions
Dong-Chen, X., Yong, C., Yang, X., Chen-Yu, S., & Li-Hua, P. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01353-3 · Cited by 469
Metadata
- Authors
- Grünewald, A., Kumar, K. R., & Sue, C. M.
- Venue
- Progress in Neurobiology
- Publisher
- Elsevier BV
- Published
- 2019-06
- Volume
- 177
- Pages
- 73-93
- ISSN
- 0301-0082 (ISSN-L)
- OpenAlex
- W2892332054
- Cited by
- 364
- References
- 281
- FWCI
- 20.30
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.